Biomarker NTRK Coverage from Every Angle

Shivaani Kummar, MD, on TRK Fusion–Positive Cancer: Clinical Implications of Larotrectinib Treatment

Posted: Sunday, August 1, 2021

Shivaani Kummar, MD, of the Oregon Health & Science University, discusses study findings on tumor types that harbor the TRK mutation, how they respond to treatment with larotrectinib, and what role this agent and oncogenic driver could play in treating solid tumors.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.